3rd Microbiome Drug Development Boston Summit

Memo

As the knowledge of the microbiome continues to deepen, fundamental understanding of mechanism of action and demonstrating causality continue to improve. As such, the Microbiome Movement has become more committed than ever to work alongside innovative researchers and industry leaders to build events that focus on applied science and translate cutting edge microbiome R&D into safe, effective and commercially successful products across a number of industry-specific verticals.



Positioned at the heart of pharmaceutical, agricultural, nutritional and animal health R&D, the Microbiome Movement continues to help accelerate the discovery, development and delivery of breakthrough solutions to global challenges to benefit human health. For each specific industry where the microbiome will have a real impact, we’re building an exclusive community for you to maximize the opportunity.



The Microbiome Drug Development Summit continues to be the industry leading forum that focuses exclusively on the development and commercialization of microbiome-based therapeutics; with case-studies from target discovery all the way through to clinical trial development, manufacturing and beyond. We will once again unite KOL’s, senior drug developers, microbiome-technology experts and breakthrough researchers to translate the human microbiome into simply effective medicines.



Early booking and group discounts are available for this event. Bring your team to cover all bases and maximize your learning opportunity through our tracked sessions. Email This email address is being protected from spambots. You need JavaScript enabled to view it. to enquire about discounts.



Brochure https://go.evvnt.com/206448-1?pid=5569,

Booking https://go.evvnt.com/206448-2?pid=5569.



Prices:

Conference Only - Register by March 23: USD 2199,

Conference Only - Standard Rate: USD 2799.



Speakers: Cathryn Nagler (ClostraBio), Christophe Bonny (Enterome Bioscience), Mark Smith (Finch Group Therapeutics), Anuk Das (Janssen Human Microbiome Institute), Jean Luc-Treillou (LNC Therapeutics), Trevor Lawley (Microbiotica), Ken Blount (Rebiotix), Daniel Couto (Vedanta Biosciences), Jessica Schneider (Takeda) & Many More.



Time: on Tuesday June 19, 2018 at 8:00 am (ends Friday June 22, 2018 at 5:00 pm).



Venue details: Seaport Hotel and World Trade Centre, 1 Seaport Lane, Boston, 02210, United States